Prior approval of independent non-executive directors
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), the governance standards of listed companies, the rules for independent directors of listed companies and other laws and regulations of the China Securities Regulatory Commission, and the articles of association of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd In accordance with the relevant provisions of the independent non-executive director system of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd., as the independent non-executive director of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”), we have reviewed the relevant proposal materials to be submitted to the 6th meeting (regular meeting) of the 8th board of directors for deliberation, and hereby express the following opinions:
1、 About the company’s re employment of accounting firm in 2022
Ernst & Young Huaming Certified Public Accountants (special general partnership) and Ernst & Young certified public accountants to be renewed this time have corresponding professional qualifications and competence, as well as experience in providing audit services for listed companies. In the process of practicing, he strictly followed the independent auditing standards for Chinese certified public accountants, earnestly fulfilled the responsibilities and obligations of the external audit institution, and was able to meet the requirements of the company’s external audit work.
This renewal does not harm the interests of the company and its shareholders, especially the minority shareholders. Agree to submit the renewal to the board of directors for deliberation.
2、 Report on the group’s daily connected / connected transactions in 2021 and the expected events of daily connected / connected transactions in 2022
These daily connected / connected transactions are necessary for the operation of the group and comply with the provisions of the company law, the securities law, the stock listing rules of the Shanghai Stock Exchange, the stock listing rules of the stock exchange of Hong Kong Limited and other relevant laws and regulations; The transaction pricing basis is fair and reasonable and in line with general commercial terms.
This matter does not harm the interests of the company and its shareholders, especially the minority shareholders. Agree to submit the matter to the board of directors for deliberation.
Independent non-executive directors: Li Ling, Tang Guliang, Wang Quandi, Yu Zishan March 19, 2002
